Maravai LifeSciences
MRVI
216 hedge funds and large institutions have $3.72B invested in Maravai LifeSciences in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 92 increasing their positions, 76 reducing their positions, and 39 closing their positions.
134% more call options, than puts
Call options by funds: $6.21M | Put options by funds: $2.65M
21% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 76
2.41% more ownership
Funds ownership: 97.31% → 99.72% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 235 → 216 (-19)
17% less capital invested
Capital invested by funds: $4.51B → $3.72B (-$789M)
41% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$118M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$75.9M |
| 3 |
Renaissance Technologies
New York
|
+$30.5M |
| 4 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$29.1M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$172M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$36.8M |
| 3 |
N
Natixis
Paris,
France
|
-$35.3M |
| 4 |
Millennium Management
New York
|
-$17.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.7M |
MRVI Hedge Fund Activity: Q2 2022 in Review
216 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2022, worth a combined $3.72B — down 17% from $4.51B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of MRVI and 23 opened new positions — a net loss of 16 holders — while 76 trimmed existing stakes and 92 added.
The largest buyer was Massachusetts Financial Services, adding an estimated $118M. The largest seller was Fidelity Investments, cutting an estimated $172M.
- 216 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2022, down from 235 in Q1 2022.
- Funds reported $3.72B of Maravai LifeSciences stock for Q2 2022, down 17% quarter-over-quarter.
- 23 funds opened new Maravai LifeSciences positions in Q2 2022 and 39 closed out, a net change of -16 holders.
- The largest Maravai LifeSciences buyer in Q2 2022 was Massachusetts Financial Services, an estimated $118M added.
- The largest Maravai LifeSciences seller in Q2 2022 was Fidelity Investments, an estimated $172M sold.
Based on aggregated 13F filings for Q2 2022.